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Background: Concurrent chemotherapy and radiation (CTRT) improves disease-free survival in locally advanced
head and neck cancer but is associated with numerous acute and chronic toxicities resulting in substantial
alterations in body mass and composition. We aim to summarize the current evidence on body composition
changes experienced by patients undergoing CTRT, examine the impact of these changes on clinical
outcomes and address potential interventions aimed at mitigating the loss.
Main Body: Loss of 20 % of pre-CTRT weight predicts poorer treatment tolerance and 30-day mortality. While
clinical practice focuses on body weight, emerging data indicates that CTRT causes profound adverse changes
in lean body mass (sarcopenia). Higher prevalence of sarcopenia predicts poorer disease-free survival as well
as overall survival, lower quality of life and functional performance. The magnitude of CTRT-induced sarcopenia is the
equivalent to that observed in a decade of aging in a healthy adult. Alterations in body composition are only explained,
in part, by decreased caloric intake; other significant predictors include body mass index, stage, and dysphagia. Lifestyle
interventions aimed at preventing loss of whole-body and especially lean mass include nutritional counseling, nutritional
supplements, dietary supplements and exercise training. Personalized nutritional counseling has been associated with
improvement in quality of life, while the benefits of feeding tube placement are inconsistent. There are inconsistently
reported benefits of resistance training in this population.
Conclusion: Patients with head and neck cancer undergoing CTRT therapy experience dramatic shifts in body
composition, including sarcopenia, which can negatively impact clinical outcomes. Efforts to understand the
magnitude, clinical importance and mechanisms of sarcopenia are needed to inform a more personalized
approach to mitigating the body composition changes associated with CTRT.
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NutritionBackground
Head and neck squamous cell carcinoma (HNSCC) is a
group of diseases arising from the upper aerodigestive
tract including the oral cavity, pharynx and larynx. There
are an estimated 59,000 cases of HNSCC diagnosed
annually in the US, representing 3 % of all newly identi-
fied cancers [1, 2]. Despite remaining relatively consist-
ent in overall incidence, the epidemiology of HNSCC* Correspondence: baxis@mskcc.org
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Western countries [3]. Once considered a disease result-
ing mostly from chronic exposure to tobacco and alco-
hol, it is now recognized that there are other causative
factors for HNSCC. One of the fastest growing subsets
of patients are those diagnosed with HNSCC tumors
arising from the oropharynx secondary to human
papilloma-virus (HPV) [4]. Patients with HPV-positive
tumors have a striking improvement in survival com-
pared with patients with historical, HPV-negative
tumors with 3-year survival of 82 % versus 57 %,
respectively (p < 0.001) [5]. Patients with HPV-
associated tumors also appear to have a lower risk ofle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Baxi et al. Cancers of the Head & Neck  (2016) 1:9 Page 2 of 7developing second primary malignancies, resulting in
longer long-term survival [5, 6]. Changing epidemi-
ology along with treatment advances have resulted in
a rise in the number of survivors of HNSCC who are
expected to live well beyond their cancer diagnosis
and treatment. Efforts are underway to better under-
stand the toxicities associated with treatment and im-
plement strategies aimed at improving the long-term
quality of life and survival in this emerging cohort of
cancer survivors [7].
Main text
Approximately 70 % of patients with HNSCC will
present with locally advanced disease and many will be
treated with concurrent chemotherapy and radiation
(CTRT). Concurrent chemotherapy and radiation is as-
sociated with significant in-field and systemic toxicities
including mucositis, dysphagia, odynophagia, nausea,
vomiting, anorexia, fatigue and dysgeusia resulting in
difficulty eating [8–10]. Furthermore, many patients
present with symptomatic tumors that lead to difficulty
eating prior to the initiation of treatment, with most
patients experiencing a loss of more than 5 % of pre-
treatment body weight in the 6 months around CTRT
[11–14]. In part, this has been exacerbated by a change
in resting energy expenditure, which furthers the loss of
lean body mass seen during and immediately after treat-
ment [11, 15]. Predictors of excessive weight loss during
treatment include higher weight at baseline, dysphagia at
diagnosis, and higher stage tumors [16]. More specific-
ally, a recent study from Denmark reported that patients
with a body mass index (BMI) ≥ 25 are three times more
likely to lose more than 5 % of baseline weight than
patients with BMI < 25 (p < 0.0001) [12].
Weight loss has been negatively associated with tumor
control and survival outcomes in HNSCC [13]. For ex-
ample, patients with early significant weight loss (defined
as >20 % loss from baseline) are more likely to die from
a treatment-related complication within 30 days of com-
pleting CTRT compared to those who do not (p = 0.029).
In a secondary analysis from the phase III SAKK 10/94
trial of hyperfractionated radiation versus cisplatin and
standard fraction radiation, Ghadjar and colleagues
found that weight loss during treatment on either arm
was common, but only weight loss experienced before
treatment was associated with decreased time to treat-
ment failure, disease free survival (DFS), and overall sur-
vival (OS) (p < 0.05 for all); weight loss occurring during
treatment was not associated with survival outcomes
[14]. The results from this study highlight two important
aspects of weight loss and HNSCC. First, patients who
are already losing weight at diagnosis are at a disadvan-
tage and may be presenting with more aggressive disease
at baseline. Second, while weight loss during treatmentis common, it is not universally prognostic. One explan-
ation for this discrepancy is that in some patients the
weight loss is caused of decreased caloric intake, while
in others weight loss is a manifestation of cachexia, or a
syndrome of dysregulated catabolism and anabolism
[17]. Historically, high-risk patients would have a percu-
taneous endoscopic gastrostomy (PEG) placed prior to
starting treatment in order to prevent decreased caloric
intake, but more recently there has been movement
away from using feeding tubes due to concerns about
delayed recovery of swallowing post-CTRT [18–20].
Interestingly, the placement of a PEG, or increased cal-
oric intake alone, does not alleviate all the weight loss
experienced during CTRT [12, 19, 21].
The weight loss experienced by patients with HNSCC
undergoing CTRT is more specifically a change in body
composition. Body weight or body mass is composed of
fat, bone, water and lean body mass and the loss of lean
body mass accounts for more than 70 % of weight lost
during CTRT [15, 22]. Loss of lean body mass in cancer
is mostly explained by sarcopenia, or loss of skeletal
muscle [23]. Patients with HNSCC undergoing CTRT
are often losing more than 5 % of their total muscle
mass in less than 6 months time which is equivalent to
the amount of muscle mass lost in the average, inactive
adult over the course of a decade [24–26]. Skeletal
muscle is the largest organ in the body and makes up
approximately 50 % of total body weight and is essential
for movement, strength, balance, body temperature
regulation and respiration. Maintaining muscle mass in-
volves a balance of protein breakdown (catabolism) and
muscle synthesis (anabolism) and is tightly regulated
through a network of external signaling pathways leading
to intracellular gene transcription [22]. Lean body mass,
mostly composed of muscle, can be measured using both
validated direct and indirect methods. Examples of pos-
sible techniques include bioelectrical impedance (BIA),
measurement of air displacement plethysmography, dual
energy x-ray (DXA, and cross-sectional imaging on com-
puted tomography (CT) or magnetic resonance imaging
(MRI) [27].
Importantly, loss of lean body mass is associated with
poorer treatment tolerance and worse cancer outcomes
[28–30]. For example, in patients receiving systemic
chemotherapy for colorectal cancer, loss of ≥ 9 % muscle
mass during a 3 month period was independently pre-
dictive of lower survival at 6 months compared to
patients who had < 9 % loss, 33 % versus 69 %, respect-
ively, despite no difference in treatment modifications
[31]. Similar associations have been described in patients
with HNSCC. Grossberg and colleagues recently re-
ported that in a cohort of 190 patients with HNSCC
treated with definitive radiation, decreased overall sur-
vival was associated with baseline sarcopenia (Hazard
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3.11) and post-radiation sarcopenia (HR 2.03, 95 % CI
1.02–4.24). However, in this analysis, weight loss alone,
without associated loss of skeletal muscle, was not asso-
ciated with worse clinical outcomes [32]. Further, when
they evaluated by subsites, skeletal muscle depletion was
associated with decreased survival in patients with non-
oropharyngeal cancer (n = 51) but not in patients with
oropharyngeal cancer (n = 139). This is a retrospective
study and while causation cannot be gleaned, the results
highlight that patients with more significant loss of skel-
etal muscle are experiencing poorer clinical outcomes.
Further, it also highlights that patients with HNSCC are
a heterogenous group and more research is necessary to
understand what, and if any, relationship exists be-
tween change in body composition and oncologic out-
comes. Emerging data suggests that patients with
HPV-related oropharyngeal cancer, generally a health-
ier and younger population at diagnosis, are also ex-
periencing significant alterations in body composition
as a result of CTRT, but that this may not negatively
impact the expected excellent clinical outcomes, at
least not at early follow-up [33].
Sarcopenia is not only relevant for oncologic out-
comes, but is predictive of worse survival in the general,
non-cancer, and population as well. It is associated with
numerous negative outcomes, including an impaired
stress response, frailty, functional impairment, lower
quality of life and decreased overall survival [34–37]. As
such, acute sarcopenia, could then explain, at least in
part, the dramatic drop in quality of life experienced by
even the most functional patients at baseline who
undergo CTRT for HNSCC [38]. In a large cross-
sectional study in people over the age of 65, sarcopenia
predicted for three times more functional impairment in
females and two times more functional impairment in
males compared to age- and sex-matched participants
with normal lean body mass [39]. Further, a large
portion of age-associated decline in cardiopulmonary
fitness, measured by VO2peak, is also explained by sarco-
penia [40]. Low cardiorespiratory fitness is an important
precursor for premature mortality regardless of under-
lying cardiovascular risk factors [41]. Altogether, this
highlights the need for studies to better understand the
impact of sarcopenia sustained during CTRT and its
impact on cardiorespiratory fitness and subsequent non-
oncologic mortality in patients with HNSCC.
The current strategies employed to combat metabolic
derangements experienced by patients during CTRT
generally focus on weight maintenance. Patients are
encouraged to eat “as many calories as they can” and
when food gets harder to swallow, supplementing it with
either oral or parenteral nutrition via a PEG [42]. How-
ever, decreased caloric intake is probably only partiallyresponsible for sarcopenia and simply increasing calories
may not address loss of muscle mass. In a review of
sarcopenia and cachexia in patients with all stages of
HNSCC, Couch and colleagues describe the dysregu-
lated metabolism and the resulting sarcopenia seen in
patients with HNSCC, suggesting that nutrition alone is
not enough to counteract the impact of body compos-
ition [21]. In spite of this, numerous studies have tried
to optimize nutritional support in patients undergoing
CTRT. Clinical trials have evaluated the benefit of indi-
vidualized nutrition counseling, oral supplementation,
and the right type and route of supplemental nutrition.
In a systematic review on the effect of nutritional inter-
ventions on weight, quality of life and mortality in
HNSCC patients treated with RT or CTRT, individual-
ized dietary counseling was beneficial on quality of life,
but the impact of tube feedings was not conclusive [43].
For example, in a prospective study of patients with
HNSCC undergoing RT, Ravasco and colleagues found
that nutritional counseling with regular foods was super-
ior to only adding nutritional supplements in maintain-
ing quality of life during and at 3 months post-RT, but
the impact of these interventions on weight was not re-
ported [44]. In a large retrospective review of patients
on RTOG 90-03, investigators performed a secondary
analysis of patients with HNSCC treated with four
different radiation strategies, Rabinovitch and col-
leagues found that beginning nutritional supplementa-
tion before starting RT was a negative prognostic
indicator for locoregional failure and death, HR 1.47,
95 % CI 1.21–1.79, p < .0001 and HR 1.41, 95 % CI
1.19–1.67, p < .0001, respectively [45]. Given the
retrospective nature of this analysis, nutritional sup-
plement was likely initiated pre-RT in patients who
presented with weight loss at diagnosis. This suggests
that patients with baseline weight loss have a worse
clinical outcomes and not that nutritional supplement
itself is having a negative impact on outcomes.
Integration of optimal nutritional support into clinical
practice for HNSCC patients has been impeded due to
the inconsistent methodology across studies, measuring
various time points and outcomes. In response, a group
of investigators published a review of the current state
of the science on nutrition and malnutrition in HNSCC
and provided a set of consensus criteria for implementa-
tion and definitions in studies on nutrition in this popu-
lation [46].
There is growing interest in using pharmacologic
supplements to combat cancer-related sarcopenia and
cachexia, including amino acids, anabolic steroids, anti-
inflammatory agents, and ghrelin-analogues, to counter-
act the deranged metabolism experienced by cancer
patients. Most research in this space has been completed
in patients with metastatic disease, often non-small cell
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patients is eicosapentaenoic acid (EPA), which is an
alpha-3-omega fatty acid found in fish oil. In vitro, EPA
has been shown to mitigate the lipolysis and inflamma-
tory underpinnings of cachexia [47, 48]. Patients with
HNSCC undergoing primary surgical approach did show
short-term benefit in loss of muscle mass with EPA, but
longer-term follow is needed [49]. A Cochrane review
on the use of EPA in cancer cachexia was completed in
2007 and recommended against regular use of EPA [50].
An alternative approach recently explored is anamorelin,
an oral ghrelin mimetic. Ghrelin is a ligand for the
growth hormone secretagogue receptor and leads toTable 1 Prospective Studies on resistance training in patients with h
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AE adverse event, CRT concurrent chemoradiotherapy, HNSCC head and neck squam
6MWD six minute walk distancerelease of growth hormone. There have been two large
phase III, double blind placebo-controlled trials of ana-
morelin in patients with cachexia resulting from unre-
sectable lung cancer. The two studies included a
combination of more 900 patients and reported im-
provement in body weight and anorexia with anamorelin
but no improvement in overall survival or strength [51].
Hopefully, pharmacologic interventions will follow a bet-
ter understanding of the exact mechanism of sarcopenia
in patients with HNSCC undergoing CTRT.
Another intervention with the potential to counteract
the negative effects of CTRT on body composition is




Adherence: 95 % for PRT group and 87 %
for control group.
Outcomes: PRT was superior to standard of
care for improving shoulder pain and
disability (p < 0.001), upper extremity
strength (p < 0.001), and upper extremity
endurance (p < 0.039)
rtially supervised PRT
with or without a
reatinine load
Adherence: 97 % in those that completed
the study with a completion rate of 70 %
Outcomes: Addition of creatinine to PRT
did not improve lean body mass (p = 0.07).
Regardless of nutritional intervention,
improvement noted after PRT in lean body
mass and maximal isometric and isokinetic
muscle strength.
dy of early versus delayed
pervised PRT (2-3x/week).
Adherence: Not reported
Outcomes: Increase in lean body mass by
4.3 % and 4.2 % in early versus delayed PRT.
Improvement larger than change after
self-chosen physical activity (p < 0.005).
Regardless of PRT start-up time, the odds
ratio of increasing LBM by more than 4 %
after PRT was 6.26 (p < 0.05).
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ard of care.
Adherence: 83 % for supervised exercise
and 62 % for exercise telephone
counseling.
Outcomes: PRT improved in fatigue and
quality of life at 6 weeks versus control.
Chair rise time (seconds) improved at 6
and 12 weeks in PRT arm versus standard
of care (-1.6 vs 0.4





Outcomes: Increased 6MWD in the
intervention arm, decreased in the control
arm with a 138 m difference between
groups (p < 0.001).
dy of immediate
ed with a 12 week
PRT (2x/week) and
ervention.
Adherence: 45.2 % in immediate group
and 61.5 % in delayed group.
Outcomes: No difference in lean body
mass or percentage body fat at 24 weeks.
ous cell cancer, PRT progressive resistance training, RT radiation therapy,
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prove clinical and survival outcomes [52–54]. In a
large systematic review and meta-analysis, Speck and
colleagues reported favorable changes of exercise on
body composition, cardiopulmonary fitness, muscular
fitness, psychological well-being, flexibility and quality
of life for cancer patients both during and after treat-
ment. While this study included 82 trials, few of the
included studies focused on patients with HNSCC
[55]. Of those that did, the majority used a progres-
sive resistance training program to improve muscle
quantity, quality and function. As sarcopenia and im-
paired physical functioning remain primary concerns
for these patients, this becomes clinically important.
Indeed, randomized studies from both breast and
prostate cancer patients have shown that resistance
training can increase lean muscle mass compared to
the control (i.e., sedentary) group [52, 54, 56, 57].
This contrasts to aerobic (or endurance) exercise
training, which primarily focuses on improving one’s
peak oxygen consumption (VO2peak) – another inde-
pendent predictor of survival in both oncologic and
non-oncologic populations alike. Together, aerobic
and resistance exercise training, are complementary to
both the cardiovascular and musculoskeletal system.
Against this background, exercise is increasingly being
explored as a potential method to combat the negative
impact of HNSCC and its treatment on patients. A prior
cross-sectional study demonstrated that HNSCC
patients get less than the recommended level of activity
at all time points; specifically, only 30.5 % are active at
baseline, falling to only 8.5 % of patients at the end of
treatment [58]. This demonstrates the great potential for
exercise to improve outcomes in this currently inactive
group. There is good data available on the benefit of
therapeutic exercises for shoulder dysfunction or trismus
resulting from fibrosis following treatment, but the
systemic impacts of exercise in HNSCC are less well
understood. We performed a review and summarized
the data from studies on progressive resistance training
in patients treated for locally advanced HNSCC (Table 1).
There was considerable heterogeneity in the study
methodology, differing in the type and timing of exer-
cise intervention, as well as the outcomes measured.
Regardless, it is clear from the control arms, when
available, that there is a negative impact of no inter-
vention [59, 60]. Much like the limitations of current
literature in nutritional interventions for HNSCC,
there is a need to standardize research in exercise in-
terventions including the type, timing, frequency and
duration of studied regimens. Only then can the re-
sults from one study be compared to the next and
provide measurable, reproducible and generalizable
interventions that are relevant to clinical practice.Conclusions
HNSCC survivors remain at a substantial risk for long-
term disability and early mortality despite achieving ini-
tial tumor control [58, 61]. Younger patients are now
presenting with HNSCC due to the epidemic of HPV-
related oropharyngeal cancer and have an expected bet-
ter overall prognosis. As these patients live longer past
diagnosis, maintaining quality of life and long-term
survival is paramount. Longitudinal studies are required
to measure the rates of recovery of weight and lean body
mass and then in turn, discover new strategies to assist
patients as they try to return to baseline functional cap-
acity after aggressive CTRT therapy. Patients with
HNSCC are unique in the challenges they face, and the
applicability of studies performed in other cancer popu-
lations may not be directly relevant to these patients;
standardized nutritional and exercise interventions are
needed for HNSCC.
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